Royalty Pharma

$50.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.50 (-2.89%) Today
-$0.10 (-0.20%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Royalty Pharma and other stocks, options, and ETFs commission-free!

About RPRX

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY. The listed name for RPRX is Royalty Pharma plc Class A Ordinary Shares.

CEO
Pablo Gerardo Legorreta
Employees
—
Headquarters
New York, New York
Founded
1996
Market Cap
31.48B
Price-Earnings Ratio
8.09
Dividend Yield
0.58
Average Volume
4.42M
High Today
$51.90
Low Today
$50.22
Open Price
$51.85
Volume
3.28M
52 Week High
$56.50
52 Week Low
$34.80

Collections

RPRX Earnings

$0.00
$0.33
$0.66
$0.99
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

BBSI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure